Understand the source comparison
Best Peptides for Sunless Tanning: Comparison
Melanotan II MC1R agonist, triggers eumelanin via cAMP-MITF pathway 0.5–1.0mg SC daily (loading), 0.5mg weekly (maintenance) 5–7 days visible, peak at 4–6 weeks SPF 3–4 per skin type increase Most researched, highest receptor affinity, requires reconstitution
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Melanotan II
- MC1R agonist, triggers eumelanin via cAMP-MITF pathway
- 0.5–1.0mg SC daily (loading), 0.5mg weekly (maintenance)
- 5–7 days visible, peak at 4–6 weeks
- SPF 3–4 per skin type increase
- Most researched, highest receptor affinity, requires reconstitution and cold storage
- Melanotan I (Afamelanotide)
- MC1R-selective agonist, FDA-approved for erythropoietic protoporphyria
- 16mg implant (controlled release over 60 days)
- 10–14 days visible, peak at 8 weeks
- SPF 2–3 per skin type increase
- Longer half-life, fewer off-target effects, not available for general research use
- α-MSH (endogenous)
- Natural melanocortin, activates MC1R at physiological levels
- N/A. Endogenous only
- Requires UV co-exposure
- SPF 2 max
- Baseline comparator, 1000× lower receptor affinity than MT-II, rapid enzymatic degradation
- Melanotan II dominates research because its receptor affinity and stability allow reproducible melanogenesis without UV co-exposure. Afamelanotide (Melanotan I) offers MC1R selectivity. It doesn't activate MC3R or MC4R, eliminating appetite and sexual side effects. But the implant delivery system and restricted availability limit its use outside clinical trials. Endogenous α-MSH serves as the mechanistic baseline, but its 20-minute half-life and dependence on UV initiation make it impractical for research modeling.